Combined C-reactive protein and Neutrophil to Lymphocyte ratio use predict survival innon-small-cell lung cancer

Inflammation markers have been shown to predict prognosis during cancer including non-small cell lung cancer (NSCLC). In particular, C-reactive protein (CRP) and Neutrophil to Lymphocyte Ratio (NLR) have been investigated. The aim of our work is to study the combination of these two markers in optim...

Full description

Saved in:

Bibliographic Details
Published in:	Tunisie Medicale Vol. 95; no. 12; p. 229
Main Authors:	Bacha, Saoussen, Sghaier, Améni, Habibech, Sonia, Cheikhrouhou, Sana, Racil, Hager, Chaouch, Naouel, Zaouri, Béchir, Chabbou, Abdellatif
Format:	Journal Article
Language:	English
Published:	Tunisia 01-12-2017
Subjects:	Adult Aged Aged, 80 and over Biomarkers, Tumor - blood C-Reactive Protein - analysis C-Reactive Protein - metabolism Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - therapy Female Humans Leukocyte Count Lung Neoplasms - blood Lung Neoplasms - diagnosis Lung Neoplasms - mortality Lung Neoplasms - therapy Lymphocytes - pathology Male Middle Aged Neutrophils - pathology Predictive Value of Tests Prognosis Retrospective Studies Survival Analysis
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Inflammation markers have been shown to predict prognosis during cancer including non-small cell lung cancer (NSCLC). In particular, C-reactive protein (CRP) and Neutrophil to Lymphocyte Ratio (NLR) have been investigated. The aim of our work is to study the combination of these two markers in optimizing prognostication in advanced NSCLC. We conducted a retrospective study that included all patients diagnosed with primary NSCLC stage IIIB or IV in our respiratory department from January 2005 to January 2013. A total of 142 male patients were included. Most of them (80.3%) had a Performance Status (PS) 0-1. Median progression-free survival (PFS) was 4.6 months (95% confidence interval (CI) 3.9-5.3) and median overall survival (OS) was 8.9 months (95%CI7.7-10.1). Survival analysis showed that CRP<10 mg/l and NLR<3.87 were predictive of better prognostic (respectively p= 0.015 and 0.049), along with chemotherapy use (p<0.0001), PS <2 (p=0.009) and age<65 (p=0.013). In addition, combined use of NLR and CRP was significantly associated with OS (p=0.0009). Median OS for patients having both high NLR (≥3.87) and CRP (≥10 mg/l) was 6.7 months. It was significantly shorter than patients having only one elevated inflammatory marker (8.8 months; p=0.025). High CRP and NLR (≥10 mg/l and ≥ 3.87 respectively) were associated with poorer survival in advanced NSCLC. Their combined use maximizes their prognostic value.
ISSN:	0041-4131